| (19) |
 |
|
(11) |
EP 2 329 830 A3 |
| (12) |
EUROPEAN PATENT APPLICATION |
| (88) |
Date of publication A3: |
|
01.02.2012 Bulletin 2012/05 |
| (43) |
Date of publication A2: |
|
08.06.2011 Bulletin 2011/23 |
| (22) |
Date of filing: 04.01.2001 |
|
| (51) |
International Patent Classification (IPC):
|
|
| (84) |
Designated Contracting States: |
|
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR |
| (30) |
Priority: |
18.01.2000 US 487368
|
| (62) |
Application number of the earlier application in accordance with Art. 76 EPC: |
|
10004747.1 / 2213291 |
|
08008871.9 / 2003207 |
|
01900829.1 / 1250455 |
| (71) |
Applicant: Isis Pharmaceuticals, Inc. |
|
Carlsbad, CA 92010 (US) |
|
| (72) |
Inventors: |
|
- Cowsert, Lex M.
New Braunfels, TX 78130 (US)
- Wyatt, Jacqueline R.
Sundance, WY 82729 (US)
|
| (74) |
Representative: Hallybone, Huw George |
|
Carpmaels & Ransford
One Southampton Row
London
WC1B 5HA
London
WC1B 5HA (GB) |
|
| |
|
| (54) |
Antisense inhibition of PTP1B expression |
(57) Antisense compounds, compositions and methods are provided for modulating the expression
of PTP1B. The compositions comprise antisense compounds, particularly antisense oligonucleotides,
targeted to nucleic acids encoding PTP1B. Methods of using these compounds for modulation
of PTP1B expression and for treatment of diseases associated with expression of PTP1B
are provided.